Please assess the completion status of the following clinical trial:

Trial Title: Novel Interventions in HIV-1 Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Documented HIV-1 positive result.~* Stable on HAART.~* Two screening viral loads of \<50 cps/ml on 2 consecutive occasions at least one month apart.~* CD4 T cell count of \>400 cells/ul.~* Nadir CD4 T cell count of \>200 cells/ul.~* Over 18 years of age.~* Willing and able to provide informed consent.~* Female subjects must not be pregnant or lactating.~* Subjects must be using adequate double barrier method of contraception as appropriate.~Exclusion Criteria:~* Prior therapeutic vaccination.~* Acute illness within 2 weeks of the start of the study.~* Prior immunomodulatory therapy (e.g. IL-2, rhGH, GCSF, GM-CSF, HU)~* Receiving immunosuppressive medication (e.g. Steroids)~* Participation in other vaccine trials currently~* Patients with diabetes mellitus type 2~* Patients with cardiac abnormalities~* Patients with pre-existing autoimmune disease~* Patients with active neoplasia~* Patients with evidence of any progression or recurrence of an underlying intra-cranial lesion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vaccine and cytokines (Type: EXPERIMENTAL): Day 0: Patients receive GTU-MultiHIV B clade vaccine 1mg/ml administered as 10 intradermal injections of 100 µl/injection.~Day 7-11: One week following this, patients receive a 5 day course of Cytokines: Aldesleukin (IL-2) Novartis UK (BD; 8 hours apart) 5 million units administered by SC injection. Sargramostim (GM-CSF) - Leukine™, Berlex Seattle US 150ug SC once daily 4 hours from rhIL-2 injections.~Day 14-18: The following week, patients rhGH (Saizen™, Serono International, Geneva, Switzerland) 4mg/day self-administered SC.~Further vaccine boosters are given on day 42 and day 84. GTU-MultiHIV B clade vaccine 1mg/ml being administered as 10 intradermal injections of 100 µl/injection.
- Vaccine alone (Type: ACTIVE_COMPARATOR): Day 0: Patients are given GTU-MultiHIV B clade vaccine 1mg/ml administered as 10 intradermal injections of 100 µl/injections.~Day 42: GTU-MultiHIV B clade vaccine as day 0.~Day 84: GTU-MultiHIV B clade vaccine as day 0.
- Cytokines alone (Type: ACTIVE_COMPARATOR): Day 7-11: One week following this, patients receive a 5 day course of Cytokines: Aldesleukin (IL-2) Novartis UK (BD; 8 hours apart) 5 million units administered by SC injection. Sargramostim (GM-CSF) - Leukine™, Berlex Seattle US 150ug SC once daily 4 hours from rhIL-2 injections.~Day 14-18: The following week, patients rhGH (Saizen™, Serono International, Geneva, Switzerland) 4mg/day self-administered SC.

Based on this trial design, predict the completion outcome and termination type (if applicable).